Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
7,191 people get DNDN articles and Market Currents by email alert.
Get email alerts on DNDN »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
-
Business Wire (May 9, 2013)
-
-
-
-
-
Business Wire (May 6, 2013)
-
-
To learn more about Seeking Alpha Pro, click here.
-
Dendreon's CEO Discusses Q2 2012 Results - Earnings Call TranscriptTue, Jul 31, 2012 • 1 Comment
-
Dendreon's CEO Discusses Q1 2012 Results - Earnings Call TranscriptMon, May 7, 2012 • 12 Comments
-
Dendreon's CEO Discusses Q4 2011 Results - Earnings Conference CallMon, Feb 27, 2012 • 10 Comments
-
Dendreon CEO Discusses Q3 2011 Results - Earnings Call TranscriptWed, Nov 2, 2011 • 2 Comments
-
Dendreon Corporation Q2 2008 Earnings Call TranscriptWed, Sep 3, 2008
-
Dendreon Corporation Q4 2007 Earnings Call TranscriptMon, Mar 31, 2008
-
Business Wire (May 9, 2013)
-
Business Wire (May 6, 2013)
-
Business Wire (Apr 24, 2013)
-
Business Wire (Mar 18, 2013)
-
Business Wire (Mar 12, 2013)
-
Business Wire (Feb 25, 2013)
-
at MarketWatch.com (Jan 11, 2013)
-
at CNBC.com (Jan 11, 2013)
-
Business Wire (Jan 7, 2013)
-
Business Wire (Dec 20, 2012)
-
Business Wire (Nov 27, 2012)
-
Business Wire (Nov 14, 2012)
-
Business Wire (Nov 2, 2012)
-
at CNBC.com (Oct 29, 2012)
-
Business Wire (Oct 29, 2012)
-
Business Wire (Oct 3, 2012)
-
Business Wire (Sep 28, 2012)
DNDN vs. ETF Alternatives
Company Description
Dendreon Corporation (“Dendreon”, the “Company”, “we”, “us”, or “our”), is a biotechnology company focused on the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients. Our product portfolio includes active... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, October 11, 2012, 1:56 PM Data from clinical trials of Provenge appears to have been analyzed differently by researchers than how Dendreon (DNDN +0.2%) told the FDA it would be. DNDN had originally said the data would be analyzed by age, using a cut-point of 65, but when the report was published its stated age was 71. The company says the discrepancy is immaterial and that Provenge is safe and effective. The FDA also stands by its decision to approve the treatment. 13 Comments [Healthcare]
- Friday, September 28, 2012, 3:43 PM Dendreon (DNDN +3.8%) bucks a weak tape today after Aetna (AET -0.4%) indicated on its website that it would pay for additional prostate cancer patients to be treated with Provenge, saying it now considers it to be medically necessary for treatment. Comment! [Healthcare, On the Move]
- Wednesday, September 19, 2012, 6:43 PM Dendreon (DNDN) says it expects to take a $25M charge associated with its reduction in headcount for employee severance and other related termination benefits during the second half of 2012 and into 2013. As previously disclosed, the company expects implementation of its restructuring plan to be completed by mid-2013. Shares +2.2% AH. Comment! [Healthcare, On the Move]
- Thursday, September 6, 2012, 9:30 AM ImmunoCellular Therapeutics (IMUC) +19.3% premarket as Maxim Group begins coverage with a Buy rating and an $18 price target. The firm says IMUC has the potential to create a new, innovative second-generation dendritic cancer vaccine to address perceived shortfalls of Dendreon's (DNDN) Provenge. If successful, the firm thinks it could become a billion-dollar product. 5 Comments [Healthcare, Quick Ideas, On the Move]
- Friday, August 31, 2012, 2:22 PM The FDA has given early approval to enzalutimide, a new prostate-cancer drug developed jointly by Medivation (MDVN +1.4%) and Astellas Pharma (ALPMY.PK). The drug - which was approved to treat men with prostate cancer that has spread or returned after prior treatment with another drug, docetaxel - will be sold under the brand name Xtandi. Dendreon (DNDN -0.6%), whose already struggling with lagging sales of its own prostrate drug, Provenge, trades down on the news. Comment! [Healthcare, On the Move]
- Wednesday, August 29, 2012, 12:40 PM Dendreon's (DNDN) Provenge may be down in its battle with Zytiga, but its not out of the fight yet according to Baird. The firm notes that while Zytiga is still taking share, its momentum is declining. At present 20% of doctors indicate less Provenge use in favor of Zytiga. This figure is down from earlier readings of 31%, and 72% of physicians indicate no change, which is up from 63%. Baird feels that the Street has a much worse scenario priced into the shares, and reiterates its $7 price target. Comment! [Healthcare]
- Friday, August 17, 2012, 4:32 PM Baird's research team still looks for more signs of a revenue uptick before issuing an upgrade on Dendreon (DNDN +2.7%), but it sees management starting a credible turnaround path and suggests some exposure given the negative sentiment and low valuation. Near-term Provenge problems seem fixable, the firm says, and cost-efficiency measures should lower cost of goods sold. 4 Comments [Healthcare, Quick Ideas]
- Wednesday, August 15, 2012, 3:05 PM Shares of Dendreon (DNDN +6.4%) spike higher on a spate of short covering in the face of more takeover rumors. Comment! [Healthcare, On the Move]
- Tuesday, July 31, 2012, 10:49 AM Dendreon (DNDN -22%) still appears to be looking for a bottom this morning, following its dismal Q2 earnings report and restructuring announcement late yesterday. Lazard, JPMorgan and Deutsche Bank have all downgraded the shares on the back of the news, while Jefferies and Baird both cut numbers. Comment! [Healthcare, On the Move, Earnings]
-
Tuesday, July 31, 2012, 9:10 AM
Premarket gainers: AH +32%. CRUS +21%. CIE +16%. LQDT +14%. KLIC +13%. ATPG +12%. ZLCS +9%. HLF +7%. VLO +6%. NOK +6%.
Losers: RLD -25%. COH -16%. DNDN -15%. HUM -10%. STX -8%. OCZ -8%. TWGP -7%. AMRN -5%. MMR -5%. Comment! [On the Move] - Monday, July 30, 2012, 7:39 PM Shares of Dendreon (DNDN) trade at their lows late in the after hours session, -18.3% to $5.03 after resuming trade earlier at $5.69. 2 Comments [Healthcare, On the Move]
- Monday, July 30, 2012, 4:39 PM Dendreon (DNDN): Q2 EPS of $0.61 misses by $0.02. Revenue of $80M misses by $6M. Company announces strategic restructuring. Shares currently halted AH. (PR) 3 Comments [Healthcare, Earnings, On the Move]
- Monday, July 30, 2012, 4:35 PM More on Dendreon (DNDN): Q2 misses across the board. Company announces a strategic restructuring which will take place over the next 12 months, and result in a headcount reduction of over 600 full time workers and reduce costs by approximately $150M annually. Shares currently halted AH. 1 Comment [Healthcare, Earnings, On the Move]
- Tuesday, July 24, 2012, 2:04 PM In addition to rumors of Dendreon (DNDN +5%) looking to sell itself, the stock also appears to be reacting to Provenge's recent inclusion on the European Medicines Agencies XEVMPD, a medicinal products dictionary that outlines a drug's basic product details. Submission of product data to the XEVMPD is now mandatory for all drugs registered in the European Union. Comment! [Healthcare, On the Move, Global & FX]
- Tuesday, July 24, 2012, 11:23 AM Dendreon (DNDN) +6.9% - although down from earlier highs - on rumors it might be trying to sell itself, with Celgene (CELG -0.2%) one name being mooted. Feeding the speculation beast is new CEO John Johnson working from New Jersey even though the company is based in Seattle. 6 Comments [On the Move, Healthcare]
- Wednesday, July 11, 2012, 1:39 PM Dendreon (DNDN -7.2%) nears its 52-week low after BofA downgrades shares to Underperform, and lowers its PT to $6 from $13. The firm expects Provenge sales to fall short of expectations for the next several quarters, keeping the business in the red, and that such a weak demand environment will limit the valuation an acquirer is willing to pay. 2 Comments [Healthcare, On the Move, Quick Ideas]
-
Brad Kenagy
ChasingtheVig $HLF 18.26%,mktlab68 $VHC 16.37%,Matt Schilling $DNDN 12.80%,Ocean Man $WTW 10.33%,realornot,$BBRY 9.98% http://bit.ly/TrJs0h - View all 0 replies
-
smokeyRose
Just unloaded $DNDN based on an Article here at SA and now it's up 76 cents...sigh...oh well won't last..legitimate P&D - View all 0 replies
-
smokeyRose
Dumped $DNDN based on an article here by a contributer whether he is right or wrong...the stock is Gone!! - View all 0 replies
-
- View all 4 replies
-
VFC's Stock House: Haha, SmokeyRose - I don't know much more than anyone else, except that $INO is up about twenty five percent this year. Nice. Good luck!
-
-
- View all 0 replies
-
- View all 0 replies
-
Brad Kenagy
Matt Schilling $DNDN 9.87% ChasingtheVig $HLF 9.34% Ocean Man $WTW 8.79% izzygemini $ZNGA 8.68% Joe Kelly $GTAT 8.49% http://bit.ly/TrJs0h - View all 0 replies
-
- View all 1 replies
-
Robbster: Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES